Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use
Open Access
- 29 August 2015
- journal article
- case report
- Published by Elsevier BV in Journal of Hepatology
- Vol. 64 (1), 234-238
- https://doi.org/10.1016/j.jhep.2015.07.041
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- G02 : Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective solar 2 trialJournal of Hepatology, 2015
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 InfectionThe New England Journal of Medicine, 2014
- O109 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-2 STUDYJournal of Hepatology, 2014
- Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical PerspectivesGastroenterology, 2014
- Drug-Induced Liver InjuryMayo Clinic Proceedings, 2014
- Daclatasvir: potential role in hepatitis CDrug Design, Development and Therapy, 2013
- An updated review on drug-induced cholestasis: Mechanisms and investigation of physicochemical properties and pharmacokinetic parametersJournal of Pharmaceutical Sciences, 2013
- HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillinNature Genetics, 2009
- Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liverGastroenterology, 2000
- Liver damage from low‐dose oral contraceptivesJournal of Internal Medicine, 1993